Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”)

類似資料

• Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
  著者:: Fradet, Y, 等
  出版事項: (2019)
• Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
  著者:: Bellmunt, J., 等
  出版事項: (2017)
• Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies
  著者:: Richard S. Finn, 等
  出版事項: (2025-06-01)
• Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial
  著者:: Nishiyama, Hiroyuki, 等
  出版事項: (2019)
• Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
  著者:: Isaacs, James, 等
  出版事項: (2020)